HSP90AA1 and colorectal carcinoma: Remarkably, previous pan-Hsp90 inhibitor trials targeting advanced CRC were performed unstratified (tanespimycin [69,70], ganetespib (STA-9090) [64,65,66], luminespib (AUY922) [71,72], and onalespip [73,74]).